Distinct longitudinal patterns of urine tumor DNA in patients undergoing surveillance for bladder cancer
Molecular Oncology · 2024-11 · 18 (11) · 2684-2695
DOI: 10.1002/1878-0261.13639 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Molecular Oncology, online erschienen am 08.05.2024. Verfasst von Hege Marie Vedeld und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Oncology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Norway. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Neoplasm Recurrence, Local, DNA, Neoplasm. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: KLINBEFORSK, Norges Forskningsråd, Helse Sør-Øst RHF.
Abstract (Originalsprache)
Cystoscopy is the gold standard for surveillance of non‐muscle invasive bladder cancer (NMIBC), but the procedure is invasive and has suboptimal accuracy. The aim of this study was to investigate the potential of analyzing urine samples for the presence of urine tumor DNA (utDNA) to replace cystoscopy for surveillance of bladder cancer recurrence. In this longitudinal, prospective, and observational study, 47 patients were followed for recurrence for 2 years, involving analysis of utDNA using the BladMetrix DNA methylation biomarker test at each cystoscopy. In total, utDNA was detected in 21/23 recurrences (91% sensitivity), including 5/5 T1, T2, and carcinoma in situ (CIS) tumors (100%) and 10/12 Ta tumors (83%), with < 1% false‐negative test results. Importantly, utDNA analysis showed the potential to reduce the number of cystoscopies by 55%, benefitting 79% of the patients. Eleven of 23 recurrences (48%) were detected earlier with utDNA than with cystoscopy, and distinct patterns of residual utDNA post‐surgery indicated minimal residual disease (MRD) or field effect in 6% and 15% of the patients, respectively. In conclusion, utDNA analysis shows high sensitivity to detect tumor recurrence, potential to reduce the number of cystoscopies, and promise to guide patient‐specific surveillance regimens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Oncology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Norway.
- Department of Urology, Oslo University Hospital, Norway.
- Danish Cancer Society Research Center, Copenhagen, Denmark.
- Department of Cancer and Inflammation Research, Institute for Molecular Medicine, University of Southern Denmark, Odense, Denmark.
- Department of Biosciences, The Faculty of Mathematics and Natural Sciences, University of Oslo, Norway.
ORCID-Profile: Heidi Pharo, Per Guldberg, Guro Elisabeth Lind
Förderung
- KLINBEFORSK
- Norges Forskningsråd
- Helse Sør-Øst RHF
Zitieren
APA
Vedeld, H. M., Pharo, H., Sørbø, A. K., Brandt-Winge, S., Five, M. B., Jeanmougin, M., Guldberg, P., Wahlqvist, R., & Lind, G. E. (2024). Distinct longitudinal patterns of urine tumor DNA in patients undergoing surveillance for bladder cancer. Molecular Oncology, 18(11), 2684-2695. https://doi.org/10.1002/1878-0261.13639
Vancouver
Vedeld HM, Pharo H, Sørbø AK, Brandt-Winge S, Five MB, Jeanmougin M, et al. Distinct longitudinal patterns of urine tumor DNA in patients undergoing surveillance for bladder cancer. Molecular Oncology. 2024;18(11):2684-2695. doi:10.1002/1878-0261.13639
BibTeX
@article{Vedeld2024,
author = {Vedeld, Hege Marie and Pharo, Heidi and Sørbø, Anne Klara and Brandt-Winge, Sara and Five, May-Britt and Jeanmougin, Marine and Guldberg, Per and Wahlqvist, Rolf and Lind, Guro Elisabeth},
title = {Distinct longitudinal patterns of urine tumor DNA in patients undergoing surveillance for bladder cancer},
journal = {Molecular Oncology},
year = {2024},
volume = {18},
number = {11},
pages = {2684--2695},
doi = {10.1002/1878-0261.13639}
}
EUVIMED